Patients diagnosed with liver disease should then undergo further serum biomarker investigations (Table 2) to (I) correlate serum and imaging results; (II) monitor disease progression over time (e.g., IL-17 for HCC prognosis over four years); and (III) contribute to studies with small patient cohorts. Here, IL17A is linked to hepatocellular carcinoma.